Negm Walaa A, Elekhnawy Engy, Mahgoub Sebaey, Ibrahim Hanaa A, Ibrahim Elberri Aya, Abo Mansour Hend E, Mosalam Esraa M, Moglad Ehssan, Alzahraa Mokhtar Fatma
Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
Int Immunopharmacol. 2024 May 10;132:111957. doi: 10.1016/j.intimp.2024.111957. Epub 2024 Mar 29.
This study investigated the antioxidant, anticancer, antibacterial properties of Dioon rzedowskii extract, which had not been previously explored. We aimed to determine the extract's effect on liver and breast cancer cell lines and on solid Ehrlich carcinoma (SEC) mouse model to investigate the underlying molecular mechanisms. Three female albino mice groups were established: a tumor control group, a group treated with 100 mg/kg of the extract (D100), and a group treated with 200 mg/kg of the extract (D200) for 16 days after tumor development. Results showed that the D. rzedowskii extract inhibited cell growth in both MCF-7 and HepG2 cells in a concentration-dependent manner. This was achieved by suppressing the cell proliferation and inducing apoptosis. The extract also improved liver, heart, and kidney functions compared to the tumor control. Furthermore, oral administration of the extract reduced tumor volume and alleviated oxidative stress in tumor tissue. The anticancer effects were associated with overexpression of p53 and Bax and downregulation of cyclin D1 expression, which was attributed to decreased phosphorylated MAPK kinases. Additionally, D. rzedowskii exhibited antibacterial activity against K. pneumoniae isolated from cancer patients. The extract inhibited bacterial growth and reduced the membrane integrity. The study suggests that D. rzedowskii has promising potential as an adjunctive therapy for cancer treatment. Further investigations are needed to explore its combined anticancer efficacy. These results emphasize the value of natural products in developing compounds with potential anticancer activity and support a paradigm shift in cancer management to improve patients' quality of life.
本研究调查了此前未被探索过的雷氏铁树提取物的抗氧化、抗癌和抗菌特性。我们旨在确定该提取物对肝癌和乳腺癌细胞系以及对实体艾氏癌（SEC）小鼠模型的影响，以研究其潜在的分子机制。建立了三组雌性白化病小鼠：一个肿瘤对照组、一个用100毫克/千克提取物处理的组（D100）和一个用200毫克/千克提取物处理的组（D200），在肿瘤形成后处理16天。结果表明，雷氏铁树提取物以浓度依赖的方式抑制MCF - 7和HepG2细胞的生长。这是通过抑制细胞增殖和诱导凋亡实现的。与肿瘤对照组相比，该提取物还改善了肝脏、心脏和肾脏功能。此外，口服该提取物可减小肿瘤体积并减轻肿瘤组织中的氧化应激。抗癌作用与p53和Bax的过表达以及细胞周期蛋白D1表达的下调有关，这归因于磷酸化的丝裂原活化蛋白激酶激酶的减少。此外，雷氏铁树对从癌症患者中分离出的肺炎克雷伯菌具有抗菌活性。该提取物抑制细菌生长并降低膜完整性。该研究表明，雷氏铁树作为癌症治疗的辅助疗法具有广阔的潜力。需要进一步研究来探索其联合抗癌疗效。这些结果强调了天然产物在开发具有潜在抗癌活性的化合物中的价值，并支持癌症管理模式的转变以提高患者的生活质量。
